Back to search

Spain· ES:109564004

ILARIS 150 MG/ML SOLUCION INYECTABLE

A medicinal product containing canakinumab, registered in Spain by Novartis Europharm Limited.

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedILARIS 150 MG/ML SOLUCION INYECTABLEATC—REGISTER NO.ES:109564004PACKS LISTED0CHECKEDSeptember 12, 2026

The record

At a glance

AEMPS CIMA (Spain)
Active substance
canakinumab
Manufacturer
Novartis Europharm Limited
Country
Spain (ES)
ATC code
—
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Canakinumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All canakinumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ilaris
  • Liechtenstein · Ilaris
  • Norway · Ilaris

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b04f6d99-694f-4941-947f-a7c8b11f7c3a
GET /v1/drugs/b04f6d99-694f-4941-947f-a7c8b11f7c3a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Uso Hospitalario",
  "estado": "{\"aut\":1500847200000}",
  "nregistro": "109564004",
  "substance": "canakinumab"
}

See everything about canakinumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.